Bruno R - Search Results

1

Evaluation of the linearity of docetaxel pharmacokinetics.

McLeod HL, Kearns CM, Kuhn JG, Bruno R. McLeod HL, et al. Among authors: bruno r. Cancer Chemother Pharmacol. 1998;42(2):155-9. doi: 10.1007/s002800050799. Cancer Chemother Pharmacol. 1998. PMID: 9654116

2

Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation.

Launay-Iliadis MC, Bruno R, Cosson V, Vergniol JC, Oulid-Aissa D, Marty M, Clavel M, Aapro M, Le Bail N, Iliadis A. Launay-Iliadis MC, et al. Among authors: bruno r. Cancer Chemother Pharmacol. 1995;37(1-2):47-54. doi: 10.1007/BF00685628. Cancer Chemother Pharmacol. 1995. PMID: 7497596 Clinical Trial.

3

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J. Lu JF, et al. Among authors: bruno r. Cancer Chemother Pharmacol. 2008 Oct;62(5):779-86. doi: 10.1007/s00280-007-0664-8. Epub 2008 Jan 19. Cancer Chemother Pharmacol. 2008. PMID: 18205003

4

Pharmacokinetics and metabolism of Taxotere (docetaxel).

Bruno R, Sanderink GJ. Bruno R, et al. Cancer Surv. 1993;17:305-13. Cancer Surv. 1993. PMID: 7907950 Review.

5

Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer.

Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P. Bruno R, et al. Cancer Chemother Pharmacol. 2005 Oct;56(4):361-9. doi: 10.1007/s00280-005-1026-z. Epub 2005 May 3. Cancer Chemother Pharmacol. 2005. PMID: 15868146

6

Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer.

Frances N, Claret L, Bruno R, Iliadis A. Frances N, et al. Among authors: bruno r. Cancer Chemother Pharmacol. 2011 Dec;68(6):1413-9. doi: 10.1007/s00280-011-1628-6. Epub 2011 Apr 8. Cancer Chemother Pharmacol. 2011. PMID: 21476101

7

Pharmacokinetics of ifosfamide are changed by combination with docetaxel: results of a phase I pharmacologic study.

Schrijvers D, Pronk L, Highley M, Bruno R, Locci-Tonelli D, De Bruijn E, Van Oosterom AT, Verweij J. Schrijvers D, et al. Among authors: bruno r. Am J Clin Oncol. 2000 Aug;23(4):358-63. doi: 10.1097/00000421-200008000-00010. Am J Clin Oncol. 2000. PMID: 10955864 Clinical Trial.

8

Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization.

Veyrat-Follet C, Bruno R, Olivares R, Rhodes GR, Chaikin P. Veyrat-Follet C, et al. Among authors: bruno r. Clin Pharmacol Ther. 2000 Dec;68(6):677-87. doi: 10.1067/mcp.2000.111948. Clin Pharmacol Ther. 2000. PMID: 11180028

9

Pharmacokinetic and pharmacodynamic properties of docetaxel: results of phase I and phase II trials.

Bruno R, Riva A, Hille D, Lebecq A, Thomas L. Bruno R, et al. Am J Health Syst Pharm. 1997 Dec 15;54(24 Suppl 2):S16-9. doi: 10.1093/ajhp/54.suppl_2.S16. Am J Health Syst Pharm. 1997. PMID: 9435928 Review.

10

Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline.

Claret L, Zheng J, Mercier F, Chanu P, Chen Y, Rosbrook B, Yazdi P, Milligan PA, Bruno R. Claret L, et al. Among authors: bruno r. Cancer Chemother Pharmacol. 2016 Sep;78(3):605-10. doi: 10.1007/s00280-016-3116-5. Epub 2016 Jul 28. Cancer Chemother Pharmacol. 2016. PMID: 27468922

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,858 results

Search Page

Filters